This thought-leader discussion is about technologies that are disrupting the life sciences and health innovation sectors today & tomorrow

About the Event

The Creative Disruption Forum is a high-level, interactive gathering built for executive leaders, senior researchers, startup founders, and biotech investors.

The Quantum Horizon Meets Real-World Science

We are witnessing a transformative shift in health innovation. While emerging paradigms like quantum computing promise to fundamentally redefine how we process biological complexity in the future, biopharma leaders today need actionable, deployable technologies to de-risk pipelines, accelerate drug discovery, and improve clinical outcomes now.

The Latest & Future Technologies Impacting Health Innovation and Life Sciences bridges the gap between tomorrow’s deep-tech horizons and today’s high-impact biological and computational breakthroughs. Hosted at ARC West London as a flagship London Life Sciences Week event, this interactive forum brings together biopharma executives, tech bio founders, investors, and academic leaders for unscripted, Chatham House Rules discussions on what is genuinely working, where the bottlenecks lie, and how to build scalable healthcare solutions.

From physical molecule-to-protein target engagement (such as CETSA® platforms) and human-relevant New Approach Methodologies (NAMs) to real-world AI applications in lead optimization, this event delivers an unfiltered "boots on the ground" look at modern translational science.

Why You Should Attend

Ground Your Strategy in Real-World Tech: Move beyond theoretical hype to evaluate proven technologies transforming R&D pipelines today—including next-gen sequencing (NGS), advanced cell & gene therapies, and biophysical target-engagement assays.

De-Risk Your Clinical Pipeline: Discover how New Approach Methodologies (NAMs), organ-on-a-chip systems, and cellular shift assays are replacing legacy models, reducing Phase II/III failure rates, and delivering more efficacious molecules into the clinic.

Unfiltered "Boots on the Ground" Insights: Hear directly from SME CEOs and biopharma R&D directors on integrating AI into discovery pipelines—sharing candid case studies on what works, what has failed, and how to avoid costly missteps.

Connect Across the West Tech District: Engage directly with key anchors across West London’s innovation ecosystem, including Imperial College London, White City Innovation District, Paddington Life Sciences, Nexus, and ARC Group.

Actionable Peer-to-Peer Workshops: Participate in interactive afternoon breakout sessions designed to co-create practical strategies for scaling deep-tech venture navigating regulatory pathways for NAMs, and optimizing R&D data.

Who Should Attends,

Biopharma & Biotech Executives (CEOs, CSOs, CTOs, R&D Directors): Looking to de-risk discovery pipelines, adopt next-generation analytical platforms, and integrate computational tools effectively.

Tech Bio Founders & SME Leadership: Seeking real-world feedback on scaling ventures, securing investment, and overcoming wet-lab validation bottlenecks.

Venture Capitalists & Deep-Tech Investors: Eager to identify high-growth opportunities across both near-term biopharma technologies and long-term deep-tech frontiers.

Academic Researchers & Translational Scientists: Interested in commercializing spinouts and bridging the gap between basic research and clinical reality.

Clinical & Regulatory Leaders: Exploring FDA/MHRA roadmaps for NAM adoption, advanced diagnostics, and cell/gene therapy pathways.

Draft Agenda

09:00 AM – 09:45 AM | Registration, Breakfast & Networking

Arrival, registration, and informal networking over breakfast.

09:45 AM – 10:00 AM | Welcome & Opening Keynote

Welcome: Deb Spencer (ARC West London)

Opening Address: Prof Tony Sedgwick & Graham Combe

Opening Keynote: The Future Promise of Quantum & Deep Tech in Healthcare — An inspiring overview of next-generation computing horizons before grounding the day in actionable, deployable technologies.

10:00 AM – 11:00 AM | Panel 1: De-Risking Pipelines — Target Engagement & New Approach Methodologies (NAMs)

Unpacking intracellular target engagement in live cells (e.g., CETSA® and biophysical mass spectrometry) alongside microphysiological systems (organ-on-a-chip, 3D organoids) to confirm compound binding and improve translational success before clinical entry.

11:00 AM – 11:30 AM | Keynote Panel: What Is Being Funded Today vs. Tomorrow?

Top VCs and life science investors discuss capital allocation across biological platforms, NAMs, and computational deep-tech, detailing how target-engagement data impacts valuation and Series funding.

11:30 AM – 11:50 AM | Refreshments & Networking Break

11:50 AM – 12:25 PM | Fireside Keynote Interview: AI in Drug Discovery — Separating Hype from Clinical Reality

An unscripted interview with a global biopharma R&D leader on deploying computational tools in active discovery, integrating predictive models with wet-

Description supplied by the event organiser.